Bausch Health Companies Inc. is on the rise, with shares climbing 1.90% in the latest trading session.
Bausch Health Companies Inc. (BHC.TO) saw its stock price increase by 1.90% during the last trading session, closing at CA$6.96. This rise comes as the company continues to develop its product offerings and strengthen its market position.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.60B
52W high
$11.97
52W low
$6.45
1W change
-0.87%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 2.6% over the next 12 months.
Consensus
No RatingAvg. Target
C$7.01
+2.6% Upside
Current Price
C$6.83
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
50.4%
Annualized
90-Day Vol
42.9%
Annualized
Trend (90d)
-35.9%
Annualized drift
90d Mean
C$6.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$6.54 | C$5.50 – C$7.79 |
| 60 trading days | C$6.27 | C$4.90 – C$8.02 |
| 90 trading days | C$6.01 | C$4.44 – C$8.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider what Bausch Health's recent stock performance means, especially with its growing product portfolio and the upcoming announcement of financial results.
1.90% Increase in Stock Price
Bausch Health's stock rose to CA$6.96, reflecting investor confidence in its future growth prospects.
Bull case
The recent stock gain shows that the market is optimistic about Bausch Health's strategic moves. The recent listing of PrOKEDI® for schizophrenia treatment in Quebec could open new revenue streams for the company.
Bear case
Despite the positive stock movement, there are still concerns about Bausch Health's profitability, as indicated by its negative profit margin. Investors should be cautious about potential volatility in the stock.
Recent Developments Fueling Growth
Bausch Health's stock performance is linked to positive changes in its product lineup. The listing of PrOKEDI® for schizophrenia treatment in Quebec is a significant step, improving access to innovative mental health treatments. This development not only expands the company's therapeutic offerings but also strengthens its position in the healthcare sector.
Upcoming Financial Results
Investors are looking forward to Bausch Health's second quarter 2026 financial results, which will be announced on July 29, 2026. The upcoming conference call will offer insights into the company's financial health and strategic direction, potentially influencing stock performance. For more details, check out our BHC.TO stock page.
Market Sentiment and Future Outlook
The market's positive reaction to Bausch Health's stock gain indicates growing confidence in the company's future. However, investors should remain cautious, as the company still faces challenges related to profitability. Keeping an eye on market trends and company developments will be crucial for making informed investment decisions.
Advertisement
